Flow cytometric analysis of Human CD371 expression on Human Peripheral Blood cells. Human Peripheral Blood cells were stained with SDT Alexa Fluor® 647 Mouse Anti-Human CD371 Antibody at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Alexa Fluor® 647 Mouse Anti-Human CD371 Antibody (S-2850)
Alexa Fluor® 647 Mouse Anti-Human CD371 Antibody (S-2850)
Price:
Regular price
$150 USD
Regular price
Sale price
$150 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD371 |
| Synonyms | C-type lectin domain family 12 member A; C-type lectin-like molecule 1 (CLL-1); Dendritic cell-associated lectin 2 (DCAL-2); Killer cell C-type lectin-like receptor L1 (hKLRL1); Myeloid inhibitory C-type lectin-like receptor (MICL); CLL1; DCAL2; KLRL1; MICL; CLEC12A |
| Location | Cell membrane |
| Accession | Q5QGZ9 |
| Clone Number | S-2850 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human Peripheral Blood cells |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 647 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD371, also known as CLEC12A, is a type II transmembrane protein with extracellular C-type lectin domains, primarily expressed on myeloid cells. It is a potential myeloid cancer stem cell marker and is considered a target for antibody-based or chimeric antigen receptor T-cell therapies. CD371 is particularly associated with DUX4-rearranged leukemia, where it is highly expressed and serves as a unique cell surface marker. Its expression is also linked to “switch” acute lymphoblastic leukemia (ALL), which has a tendency to switch to monocyte-like cells upon corticosteroid treatment.
Picture
Picture
FC
